Skip to content

Effect of Green Tea (Epigallocatechin Gallate) on Albuminuria in Patients With Diabetic Nephropathy.

A Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Green Tea on Albuminuria in Patients With Diabetic Nephropathy and Use of Maximum Dose of ACE-I and / or Angiotensin II Receptor Blocker.

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01923597
Enrollment
50
Registered
2013-08-15
Start date
2013-11-30
Completion date
2015-03-31
Last updated
2016-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy, Hypertension

Keywords

Proteinuria, Oxidative stress, Epigallocatechin gallate

Brief summary

The purpose of this study is to determine the safety and effect of green tea (epigallocatechin gallate) in albuminuria in diabetic patients and nephropathy.

Detailed description

Clinical, prospective, randomized, double-blind, placebo-controlled, with analysis by intention to treat. 50 individuals will be selected with a diagnosis of diabetes / hypertension and has been followed in Diabetic Nephropathy Clinic of the Faculty of Medical Sciences, University of Campinas (UNICAMP). Participants are divided into 02 groups: 1) 25 patients treated with maximum dose of ACE-I and / or angiotensin II receptor blocker (ARBs) + Placebo (absence of epigallocatechin gallate) and 2) treated 25 patients with maximum dose of ACE-I and / or ARBs + green tea (epigallocatechin gallate). The patients will receive four capsules Polyphenol E - epigallocatechin gallate (Polyphenon Pharma, NY) per day, corresponding to 800 mg of epigallocatechin gallate (EGCG), or placebo (no epigallocatechin gallate) for 3 months. Patients will not be aware of the treatment they are receiving. The subjects will be allocated for the treatment or placebo, stratified by sex. To avoid the influence of researchers, the randomization list will be generated and maintained by trained personnel in a different location from the study. Before treatment and immediately after 3 months of treatment will be obtained in the primary outcome measures (albuminuria) and secondary (plasma metabolites of flavonoids, level of urinary F2-isoprostane and 8-hydroxydeoxyguanosine). In these same times will be obtained: blood biochemistry (glucose, glycosylated hemoglobin, urea, creatinine, sodium, potassium, blood count, calcium, phosphorus, cholesterol, LDL, HDL, triglycerides, uric acid), 3 samples of first morning urine to determine albuminuria, glomerular filtration rate (GFR), blood pressure measurement of 24 h, physical examination, weight, blood pressure and heart rate. Adherence to the study will be evaluated by weekly phone and the expected increase in plasma of flavonoids using the green tea (epigallocatechin gallate). The antihypertensive drug may be adjusted to obtain the desired pressure (\<130/80 mmHg).

Interventions

DRUGGreen tea extract

200mg/capsule Administered orally 4 capsules per day For 3 months

Sponsors

University of Campinas, Brazil
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* 18 years or more * prior diagnosis of diabetes mellitus (DM) * persistent micro-or macroalbuminuria (urinary albumin excretion\> 30 mg / g creatinine (AUC) in 3 consecutive measurements on different days) * glycated hemoglobin \<10% * maximum dose of ACE-I and / or ARBs.

Exclusion criteria

* diagnosis of autoimmune diseases, HIV, hepatitis, cancer, inflammatory disease * pregnant or lactating patients * glomerular filtration rate (GFR) \<30 ml/min/1, 73m2 (estimated by the MDRD and the Cockcroft-Gault formula) * presence of kidney disease unrelated to diabetes * chronic urinary tract infection * diagnosis of congestive heart failure (CHF) New York Heart Association (NYHA) class III or IV * recent history (\<6 months) unstable angina, myocardial infarction, stroke, coronary intervention * history of alcohol and / or drugs * mental incapacity to understand the informed consent * intolerance to green tea

Design outcomes

Primary

MeasureTime frameDescription
Effect of green tea (epigallocatechin gallate) in albuminuria in diabetic patients and nephropathy.After 3 months of treatmentMean of 3 urinary albumin to creatinine ratio.

Secondary

MeasureTime frameDescription
Effect of green tea (epigallocatechin gallate) on oxidative stress in patients with diabetic nephropathy.After 3 months of treatmentUrinary levels of F2-isoprostane and 8-hydroxydeoxyguanosine
Effect of green tea (epigallocatechin gallate) on blood glucose control in patients with diabetic nephropathy.After 3 months of tretatmentGlycemia and glycated hemoglobin
Effect of green tea (epigallocatechin gallate) on plasma lipids in patients with diabetic nephropathy.After 3 months of treatmentPlasma levels of HDL.
Effect of green tea (epigallocatechin gallate) on plasma metabolites of flavonoids in patients with diabetic nephropathy.After 3 months of treatmentPlasma levels of epigallocatechin gallate and epicatechin.
Effect of green tea (epigallocatechin gallate) on blood pressure in patients with diabetic nephropathy.After 3 months of treatment24 h blood pressure monitoring

Other

MeasureTime frameDescription
Effect of Green Tea (epigallocatechin gallate) in the glomerular filtration rate in patients with diabetic nephropathy.After 3 months of treatmentEstimated by Modification of Diet in Renal Disease (MDRD) formula.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026